Equities research analysts expect Galectin Therapeutics Inc. (NASDAQ:GALT) to post earnings of ($0.06) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Galectin Therapeutics’ earnings. Galectin Therapeutics reported earnings per share of ($0.08) in the same quarter last year, which would suggest a positive year-over-year growth rate of 25%. The firm is scheduled to issue its next earnings results on Wednesday, March 4th.
According to Zacks, analysts expect that Galectin Therapeutics will report full year earnings of ($0.35) per share for the current financial year. For the next year, analysts expect that the business will report earnings of ($0.41) per share, with EPS estimates ranging from ($0.51) to ($0.31). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that follow Galectin Therapeutics.
Galectin Therapeutics (NASDAQ:GALT) last posted its earnings results on Tuesday, November 12th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.03.
In other news, major shareholder Fund L.P. 10X sold 17,000 shares of the stock in a transaction on Thursday, October 10th. The shares were sold at an average price of $3.73, for a total value of $63,410.00. The sale was disclosed in a filing with the SEC, which is available at this link. 40.70% of the stock is owned by insiders.
Hedge funds have recently modified their holdings of the stock. Vivaldi Capital Management LLC purchased a new position in Galectin Therapeutics during the 2nd quarter valued at $44,000. Squarepoint Ops LLC increased its stake in Galectin Therapeutics by 37.5% in the third quarter. Squarepoint Ops LLC now owns 13,901 shares of the company’s stock worth $51,000 after purchasing an additional 3,788 shares during the period. Commonwealth Equity Services LLC increased its stake in Galectin Therapeutics by 25.1% in the second quarter. Commonwealth Equity Services LLC now owns 15,247 shares of the company’s stock worth $63,000 after purchasing an additional 3,059 shares during the period. Centaurus Financial Inc. increased its stake in Galectin Therapeutics by 20,098.8% in the second quarter. Centaurus Financial Inc. now owns 16,563 shares of the company’s stock worth $69,000 after purchasing an additional 16,481 shares during the period. Finally, Amussen Hunsaker Associates LLC bought a new stake in shares of Galectin Therapeutics during the second quarter worth $71,000. 16.48% of the stock is owned by hedge funds and other institutional investors.
Galectin Therapeutics stock opened at $2.99 on Friday. Galectin Therapeutics has a 52-week low of $2.82 and a 52-week high of $6.06. The firm’s fifty day moving average is $3.58 and its 200 day moving average is $3.71. The company has a market cap of $170.09 million, a price-to-earnings ratio of -7.87 and a beta of 2.99.
Galectin Therapeutics Company Profile
Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate includes GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.
Further Reading: Mutual funds are not immune from market timing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.